190 related articles for article (PubMed ID: 29769196)
1. An
Lu X; Pan X; Wu CJ; Zhao D; Feng S; Zang Y; Lee R; Khadka S; Amin SB; Jin EJ; Shang X; Deng P; Luo Y; Morgenlander WR; Weinrich J; Lu X; Jiang S; Chang Q; Navone NM; Troncoso P; DePinho RA; Wang YA
Cancer Res; 2018 Jul; 78(14):3823-3833. PubMed ID: 29769196
[TBL] [Abstract][Full Text] [Related]
2. MiR-182 promotes prostate cancer progression through activating Wnt/β-catenin signal pathway.
Wang D; Lu G; Shao Y; Xu D
Biomed Pharmacother; 2018 Mar; 99():334-339. PubMed ID: 29353209
[TBL] [Abstract][Full Text] [Related]
3. A Pygopus 2-Histone Interaction Is Critical for Cancer Cell Dedifferentiation and Progression in Malignant Breast Cancer.
Saxena M; Kalathur RKR; Rubinstein N; Vettiger A; Sugiyama N; Neutzner M; Coto-Llerena M; Kancherla V; Ercan C; Piscuoglio S; Fischer J; Fagiani E; Cantù C; Basler K; Christofori G
Cancer Res; 2020 Sep; 80(17):3631-3648. PubMed ID: 32586983
[TBL] [Abstract][Full Text] [Related]
4. Targeting the chromatin effector Pygo2 promotes cytotoxic T cell responses and overcomes immunotherapy resistance in prostate cancer.
Zhu Y; Zhao Y; Wen J; Liu S; Huang T; Hatial I; Peng X; Al Janabi H; Huang G; Mittlesteadt J; Cheng M; Bhardwaj A; Ashfeld BL; Kao KR; Maeda DY; Dai X; Wiest O; Blagg BSJ; Lu X; Cheng L; Wan J; Lu X
Sci Immunol; 2023 Mar; 8(81):eade4656. PubMed ID: 36897957
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway.
Ren D; Yang Q; Dai Y; Guo W; Du H; Song L; Peng X
Mol Cancer; 2017 Jul; 16(1):117. PubMed ID: 28693582
[TBL] [Abstract][Full Text] [Related]
6. The role of Pygo2 for Wnt/ß-catenin signaling activity during intestinal tumor initiation and progression.
Talla SB; Brembeck FH
Oncotarget; 2016 Dec; 7(49):80612-80632. PubMed ID: 27811361
[TBL] [Abstract][Full Text] [Related]
7. Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt/β-catenin pathway.
Zhang ZM; Wu JF; Luo QC; Liu QF; Wu QW; Ye GD; She HQ; Li BA
Oncogene; 2016 Sep; 35(36):4787-97. PubMed ID: 26876203
[TBL] [Abstract][Full Text] [Related]
8. Capn4 expression is modulated by microRNA-520b and exerts an oncogenic role in prostate cancer cells by promoting Wnt/β-catenin signaling.
Ren W; Wang D; Li C; Shu T; Zhang W; Fu X
Biomed Pharmacother; 2018 Dec; 108():467-475. PubMed ID: 30241050
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of Myc-Dependent Mitotic Gene Expression by the Pygopus2 Chromatin Effector.
Andrews PGP; Popadiuk C; Belbin TJ; Kao KR
Cell Rep; 2018 May; 23(5):1516-1529. PubMed ID: 29719262
[TBL] [Abstract][Full Text] [Related]
10. Pygo2 functions as a prognostic factor for glioma due to its up-regulation of H3K4me3 and promotion of MLL1/MLL2 complex recruitment.
Zhou C; Zhang Y; Dai J; Zhou M; Liu M; Wang Y; Chen XZ; Tang J
Sci Rep; 2016 Feb; 6():22066. PubMed ID: 26902498
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-744 promotes prostate cancer progression through aberrantly activating Wnt/β-catenin signaling.
Guan H; Liu C; Fang F; Huang Y; Tao T; Ling Z; You Z; Han X; Chen S; Xu B; Chen M
Oncotarget; 2017 Feb; 8(9):14693-14707. PubMed ID: 28107193
[TBL] [Abstract][Full Text] [Related]
12. Abnormal nuclear expression of Pygopus-2 in human primary hepatocellular carcinoma correlates with a poor prognosis.
Zhang S; Li J; He F; Wang XM
Histopathology; 2015 Aug; 67(2):176-84. PubMed ID: 25545771
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
14. The Pygo2-H3K4me2/3 interaction is dispensable for mouse development and Wnt signaling-dependent transcription.
Cantù C; Valenta T; Hausmann G; Vilain N; Aguet M; Basler K
Development; 2013 Jun; 140(11):2377-86. PubMed ID: 23637336
[TBL] [Abstract][Full Text] [Related]
15. TRIB1 supports prostate tumorigenesis and tumor-propagating cell survival by regulation of endoplasmic reticulum chaperone expression.
Mashima T; Soma-Nagae T; Migita T; Kinoshita R; Iwamoto A; Yuasa T; Yonese J; Ishikawa Y; Seimiya H
Cancer Res; 2014 Sep; 74(17):4888-97. PubMed ID: 24962028
[TBL] [Abstract][Full Text] [Related]
16. Frequently rearranged in advanced T‑cell lymphomas‑1 demonstrates oncogenic properties in prostate cancer.
Zhang W; Xiong H; Zou Y; Xu S; Quan L; Yuan X; Xu N; Wang Y
Mol Med Rep; 2016 Oct; 14(4):3551-8. PubMed ID: 27599661
[TBL] [Abstract][Full Text] [Related]
17. miR-539 inhibits prostate cancer progression by directly targeting SPAG5.
Zhang H; Li S; Yang X; Qiao B; Zhang Z; Xu Y
J Exp Clin Cancer Res; 2016 Apr; 35():60. PubMed ID: 27037000
[TBL] [Abstract][Full Text] [Related]
18. Wnt/β-catenin-dependent acetylation of Pygo2 by CBP/p300 histone acetyltransferase family members.
Andrews PG; Kao KR
Biochem J; 2016 Nov; 473(22):4193-4203. PubMed ID: 27647933
[TBL] [Abstract][Full Text] [Related]
19. PHF21B overexpression promotes cancer stem cell-like traits in prostate cancer cells by activating the Wnt/β-catenin signaling pathway.
Li Q; Ye L; Guo W; Wang M; Huang S; Peng X
J Exp Clin Cancer Res; 2017 Jun; 36(1):85. PubMed ID: 28645312
[TBL] [Abstract][Full Text] [Related]
20. PRKAR2B promotes prostate cancer metastasis by activating Wnt/β-catenin and inducing epithelial-mesenchymal transition.
Sha J; Han Q; Chi C; Zhu Y; Pan J; Dong B; Huang Y; Xia W; Xue W
J Cell Biochem; 2018 Sep; 119(9):7319-7327. PubMed ID: 29761841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
